Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins - il Centro Tirreno - Quotidiano online
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
22
Ven, Ott

Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically

promising drug candidates.  

Its recently expanded production capacity enables Eleva to conduct clinical studies of its drug candidates. Among the first ones is factor H which will be developed through phase II. Up to 2,500 l will be produced in state-of-the-art single-use reactors at a GMP site.  

Eleva's moss-based platform offers unique advantages for recombinant protein development, such as:  

Eleva is leveraging those advantages to produce complex proteins for future therapies, such as 2nd generation oncological therapeutics, or virus-like-particles (VLP) for vaccine development.  

Ralf Smit, CBO of Eleva: "With production scaling up, we can now offer to develop difficult-to-express therapeutic proteins in collaboration with partners in the pharmaceutical industry. We look forward to our moss platform unlocking the very promising potential of complex candidates for the benefit of patients." 

About Eleva 

Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners. The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases. 

Press contact  

eleva GmbHFabienne Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.: +49 761 470 990www.elevabiologics.com